-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In April, no less than 30 pharmaceutical companies released their first-quarter performance reports.
Among them, there were 2 companies whose net profit increased by more than 100%, namely Shanghai Yizhong and Wantai Bio
.
Among them, Shanghai Yizhong's main income in the first quarter of 2022 was 34.
342 million yuan; net profit attributable to the parent increased by 658.
55% year-on-year to 30.
7445 million yuan; non-net profit increased by 436.
17% year-on-year to 23.
1216 million yuan
.
It is understood that, at present, Shanghai Yizhong's operating income mainly comes from the sales of the product, paclitaxel polymer micelles for injection
.
The product was independently developed by the company and was approved for marketing on October 26, 2021.
The approved indication is non-small cell lung cancer
.
In other words, the product has been on the market for less than half a year, and sales have grown by 7 times
.
Shanghai Yizhong said that the company is still committed to promoting the expansion of clinical trials of paclitaxel micelles for small cell lung cancer, breast cancer, ovarian cancer, gastric cancer and other cancers
.
According to the industry, the path chosen by Shanghai Yizhong at this stage is to transform from a single R&D enterprise to a pharmaceutical enterprise integrating R&D, production and sales
.
With the promotion of the sales of paclitaxel micelles, and the parallel research and development of multiple indications and cabazitaxel, this year may become a key year for the development of Shanghai Yizhong
.
Wantai Bio's 2022 quarterly report data shows that in the first quarter of 2022, the company's operating income increased by 284.
85% year-on-year to 3.
171 billion yuan; the net profit attributable to the parent increased by 360.
18% year-on-year to 1.
331 billion yuan; the net profit after deducting non-returning to the parent was realized.
A year-on-year increase of 367.
75% to 1.
315 billion yuan; net operating cash flow increased by 483.
68% year-on-year to 448 million yuan
.
It is understood that "vaccine" and "reagent" are the main product components of Wantai Bio.
Among them, "vaccine" is growing rapidly and is the main driving force for Wantai Bio's performance growth.
In 2021, it will far exceed "reagent" and become Wantai Bio major components of the product
.
Among them, the domestic 2-valent HPV vaccine independently developed by Wantai Bio has achieved rapid growth since it was launched on the market in May 2020.
With the completion of production expansion in 2021, the annual production capacity has been increased to 30 million, and it is expected to continue to increase in the future; 9-valent HPV Vaccines, chickenpox vaccines, etc.
are in phase III clinical stage, and the future can be expected
.
On April 26, 2022, Wantai Biotech added a new institution to forecast its 2022 annual performance
.
A total of 14 institutions have accumulated in 6 months, and the average net profit in 2022 is predicted to be 4.
024 billion yuan, a year-on-year increase of 99.
06%
.
Recently, Wantai Bio has also attracted much attention from investors.
It was surveyed by 13 institutions on April 20, 2022
.
Among them, there are 10 fund management companies, 2 securities companies and 1 insurance asset management company
.
In addition to the above two companies, among the pharmaceutical companies that released their performance reports in April, 22 had a net profit growth of 0-100%.
For example, Xin Litai achieved a year-on-year increase of 22.
11% in operating income in the first quarter of this year, reaching 935.
2409 million yuan; The total profit increased by 43.
38% year-on-year to 267.
8039 million yuan; the net profit attributable to shareholders of the listed company increased by 53.
09% year-on-year to 237.
3774 million yuan
.
In the first quarter of 2022, Zuoli Pharmaceutical achieved a year-on-year increase of 29.
18% in operating income to 439,416,764.
79 yuan; net profit attributable to shareholders of listed companies increased by 56.
97% year-on-year to 68,746,697.
37 yuan
.
In the first quarter of 2022, Aoxiang Pharmaceutical's operating income increased by 42.
45% year-on-year to 205,113,465.
95 yuan; the net profit attributable to shareholders of the listed company increased by 61.
18% year-on-year to 70,722,644.
75 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Among them, there were 2 companies whose net profit increased by more than 100%, namely Shanghai Yizhong and Wantai Bio
.
Among them, Shanghai Yizhong's main income in the first quarter of 2022 was 34.
342 million yuan; net profit attributable to the parent increased by 658.
55% year-on-year to 30.
7445 million yuan; non-net profit increased by 436.
17% year-on-year to 23.
1216 million yuan
.
It is understood that, at present, Shanghai Yizhong's operating income mainly comes from the sales of the product, paclitaxel polymer micelles for injection
.
The product was independently developed by the company and was approved for marketing on October 26, 2021.
The approved indication is non-small cell lung cancer
.
In other words, the product has been on the market for less than half a year, and sales have grown by 7 times
.
Shanghai Yizhong said that the company is still committed to promoting the expansion of clinical trials of paclitaxel micelles for small cell lung cancer, breast cancer, ovarian cancer, gastric cancer and other cancers
.
According to the industry, the path chosen by Shanghai Yizhong at this stage is to transform from a single R&D enterprise to a pharmaceutical enterprise integrating R&D, production and sales
.
With the promotion of the sales of paclitaxel micelles, and the parallel research and development of multiple indications and cabazitaxel, this year may become a key year for the development of Shanghai Yizhong
.
Wantai Bio's 2022 quarterly report data shows that in the first quarter of 2022, the company's operating income increased by 284.
85% year-on-year to 3.
171 billion yuan; the net profit attributable to the parent increased by 360.
18% year-on-year to 1.
331 billion yuan; the net profit after deducting non-returning to the parent was realized.
A year-on-year increase of 367.
75% to 1.
315 billion yuan; net operating cash flow increased by 483.
68% year-on-year to 448 million yuan
.
It is understood that "vaccine" and "reagent" are the main product components of Wantai Bio.
Among them, "vaccine" is growing rapidly and is the main driving force for Wantai Bio's performance growth.
In 2021, it will far exceed "reagent" and become Wantai Bio major components of the product
.
Among them, the domestic 2-valent HPV vaccine independently developed by Wantai Bio has achieved rapid growth since it was launched on the market in May 2020.
With the completion of production expansion in 2021, the annual production capacity has been increased to 30 million, and it is expected to continue to increase in the future; 9-valent HPV Vaccines, chickenpox vaccines, etc.
are in phase III clinical stage, and the future can be expected
.
On April 26, 2022, Wantai Biotech added a new institution to forecast its 2022 annual performance
.
A total of 14 institutions have accumulated in 6 months, and the average net profit in 2022 is predicted to be 4.
024 billion yuan, a year-on-year increase of 99.
06%
.
Recently, Wantai Bio has also attracted much attention from investors.
It was surveyed by 13 institutions on April 20, 2022
.
Among them, there are 10 fund management companies, 2 securities companies and 1 insurance asset management company
.
In addition to the above two companies, among the pharmaceutical companies that released their performance reports in April, 22 had a net profit growth of 0-100%.
For example, Xin Litai achieved a year-on-year increase of 22.
11% in operating income in the first quarter of this year, reaching 935.
2409 million yuan; The total profit increased by 43.
38% year-on-year to 267.
8039 million yuan; the net profit attributable to shareholders of the listed company increased by 53.
09% year-on-year to 237.
3774 million yuan
.
In the first quarter of 2022, Zuoli Pharmaceutical achieved a year-on-year increase of 29.
18% in operating income to 439,416,764.
79 yuan; net profit attributable to shareholders of listed companies increased by 56.
97% year-on-year to 68,746,697.
37 yuan
.
In the first quarter of 2022, Aoxiang Pharmaceutical's operating income increased by 42.
45% year-on-year to 205,113,465.
95 yuan; the net profit attributable to shareholders of the listed company increased by 61.
18% year-on-year to 70,722,644.
75 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
